Ebolaviruses, transmission and Bundibugyo

Ebola as a disease and ebolaviruses as a group of viruses

In public communication people say “Ebola”, but more precisely we distinguish between the disease and the specific ebolaviruses. For the current outbreak it is essential to identify the causative agent: the available vaccines and registered monoclonal antibodies were developed mainly for Ebola virus (EBOV; species Orthoebolavirus zairense, in older literature Zaire ebolavirus), whereas the current outbreak in the DRC and Uganda is caused by Bundibugyo virus (BDBV).

Sources: CDC: Ebola Disease Basics, WHO Ebola disease fact sheet, ICTV Filoviridae profile.

Transmission and clinical picture

Bundibugyo virus in the current 2026 outbreak

Bundibugyo virus (BDBV) is a single-stranded, negative-sense RNA virus of the family Filoviridae. Its genome is approximately 18.9 kb and is not segmented. The current outbreak is therefore not a “new kind of Ebola” in the sense of an unknown artificial pathogen; it is a known ebolavirus belonging to the species Orthoebolavirus bundibugyoense, first described during an outbreak in Uganda in 2007.

The first three near-complete genomes from the current outbreak were published on 18 May 2026. Subsequent updates on virological.org added further sequences from Bunia, Katwa, Rwampara, Nyankunde and from a patient treated in Germany. The publicly discussed analyses therefore work with smaller, precisely defined sets of genomes from the current outbreak, whereas Pathoplexus as a database contains a broader listing, including historical records from 2007 and 2012. At the 26 August check, Pathoplexus/LAPIS aggregation showed 677 versioned database entries for outbreak Bdbv-2026: 655 from the DRC, 20 from Uganda and 2 from Germany, unchanged from the previous published version. The two German entries released on 23 July share accession PP_0079G2P and differ by version; they are therefore not two new clinical cases or evidence of transmission in Germany. This figure cannot be taken as a clinical case count, the number of genomes used in a specific analysis, or evidence of a mutation changing transmissibility or severity.

Media reports on 6 August quoted the Africa CDC director-general raising a hypothesis that studies are only now intended to investigate. Genetic change is expected in an RNA virus; a claim about altered biological properties would require evidence for a specific variant and its functional or epidemiological effect. No such public expert evidence was found by the cut-off.

A preliminary phylogenetic analysis supports the interpretation of a new zoonotic introduction rather than a continuation of an older epidemic. The time tree from the virological.org update places the estimate of the common ancestor in a broad interval of roughly late February to late April 2026; the uncertainty is large, however, because data are still scarce and sampling is not even across the affected areas.

A separate molecular-evolutionary reanalysis published on virological.org on 4 June works with 10 sequences linked to the current outbreak that were available in the Pathoplexus database as of 28 May. The authors cautiously estimate the common ancestor of the sampled viruses at early to mid-March 2026, report 23 unique mutations, and most estimates of the reproduction number come out above 1. At the same time they themselves stress that this is a preliminary result with considerable uncertainty owing to the small number of sequences, the short time window and possible selection bias.

A new genomic epidemiology analysis by INRB and partners, posted on 9 July, starts from a dataset of 139 DRC genomes from samples collected between 2 May and 23 June across 16 health zones. The initial dataset includes 138 genomes from Ituri and one from North Kivu; after quality control, individual phylogenetic analyses use smaller subsets. The median estimate of the common ancestor falls around mid-March, with a broader range from roughly February to April, and the estimated doubling time is 11.7 days (95% HPD 6.8–17.5 days). A cautious signal of possible slowing in early June remains highly uncertain. These are model-based findings from the available genomic sample, not a direct case count or a precise date of zoonotic introduction.

On 10 August, WHO Regional Director for Africa Mohamed Yakub Janabi was reported by AP as saying that sequencing indicated the outbreak began in February and that some early cases may have been attributed to malaria or typhoid. We found no separate official transcript of that statement. Its first part is nevertheless supported by two public expert sources: the INRB-led analysis places the common ancestor on 8 or 15 March, depending on the model, with uncertainty intervals extending from 1 or 9 February into April; a CDC model also allows for a zoonotic spillover around mid-to-late February. February is therefore a credible retrospective possibility, not a directly observed or precisely established outbreak start date.

On 11 June, Nature Medicine published a short scientific communication on the Ugandan index case. This is a newly published analysis of an older event: the patient travelled from the DRC to Uganda, was admitted to a private hospital in Kampala on 11 May and died on 14 May. A post-mortem sample was positive for orthoebolavirus RNA and RT-qPCR confirmed BDBV; sequencing achieved 99% genome coverage at a depth of at least 100×. The authors report that the 2026 genome forms a distinct lineage roughly equidistant from the Butalya 2007–2008 and Isiro 2012 variants.

Diagnostically, it is important that a negative GeneXpert test targeting Ebola virus (EBOV) does not rule out Bundibugyo virus. The first shared laboratory report describes detection using a broader filovirus PCR test and rapid sequencing.

On 2 July, WHO added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing. This is intended to speed access to reliable laboratory diagnosis for early case detection, clinical care, surveillance and response. It is not a treatment, vaccine or home rapid test for the public. WHO also states that, with support from WHO and Africa CDC, laboratory capacity in the DRC has expanded from the central INRB laboratories to a network of 10 laboratories in affected provinces, with reported capacity above 2,000 tests per day.

Sources: virological.org: Initial genomes from May 2026 Bundibugyo Virus Disease Outbreak, virological.org: molecular evolutionary analysis, 4 June 2026, virological.org: genomic epidemiology, 9 July 2026, CDC MMWR: modelling a possible transmission start, 5 June 2026, AP: statement by the WHO Regional Director for Africa, 10 August 2026, Pathoplexus: Ebola-BDBV, Pathoplexus LAPIS aggregation by outbreak, Pathoplexus LAPIS aggregation by outbreak and country, Pathoplexus LAPIS aggregation by release date, outbreak and country, Nature Medicine: Uganda index case, 11 June 2026, WHO temporary recommendations, 22 May 2026, WHO: first BDBV diagnostic test in Emergency Use Listing, 2 July 2026.